Dyne Therapeutics, Inc. (DYN) Cash Flow Statement

The OCF/NI ratio of 0.73 in Q2 2026 suggests that a substantial portion of the net loss is non-cash, primarily stock-based compensation and depreciation. However, the ratio has fluctuated between 0.73 and 1.20 over the past ten quarters, indicating that working capital changes and other accruals can swing the relationship. Investors should monitor this ratio as the company scales clinical trials, as a persistently low ratio may signal deteriorating cash conversion efficiency.

The sequential improvement from Q1 to Q2 is misleading; the overall trend shows a clear acceleration in cash consumption, with quarterly FCF declining from -$55.7M in Q2 2024 to -$131.8M in Q2 2026. This aligns with the 51% sequential jump in R&D spending noted in the income statement analysis, likely tied to BLA preparation and expanded trials. The lack of revenue means FCF margins are undefined, and the company remains entirely dependent on external financing to sustain operations.

The extremely low CapEx relative to the scale of operations indicates that Dyne is not investing in physical infrastructure, likely outsourcing manufacturing and relying on contract research organizations. However, as the company approaches commercialization, significant capital investment in manufacturing capacity may be required, which could materially increase future cash burn. The current CapEx/Revenue ratio is not meaningful given zero revenue, but investors should watch for a step-up in capital spending as a leading indicator of commercial readiness.

The positive working capital contribution in Q2 2026 likely reflects timing of payments to vendors and clinical trial sites, while the negative contribution in Q1 suggests accelerated payments. These swings are typical for a clinical-stage biotech with lumpy trial expenses and no revenue to smooth the cycle. The absence of inventory and receivables means working capital dynamics are driven entirely by payables and accrued expenses, which can be managed to some extent but may also signal cash conservation efforts.

The absence of capital returns is consistent with a pre-revenue biotech conserving cash for its core mission. The company's $893M cash cushion, as noted in the company intelligence, provides a runway of roughly five quarters based on the current burn rate, but this assumes no additional financing. Management's historical ability to raise capital at opportune times suggests a disciplined approach, but the accelerating burn rate and lack of revenue generation mean that dilution is likely before any potential commercialization.

The cumulative gap between net income and operating cash flow is relatively small, suggesting that non-cash charges like stock-based compensation are largely offset by working capital inflows. This implies that the reported losses are a reasonable proxy for actual cash consumption, which is a negative signal for a company with no revenue. The divergence may widen if the company capitalizes more costs or if working capital swings become more pronounced, but currently the earnings quality is not artificially inflating cash burn.